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Upon induction of differentiation, growth-arrested (G1 phase)
3T3-L1 preadipocytes express CCAAT/enhancer binding protein-
(C/EBP), initiating a transcriptional cascade. C/EBP immediately
undergoes a priming phosphorylation (on Thr188) by MAPK/ERK.
However, the acquisition of DNA binding and transactivation
capacity of C/EBP is delayed until further phosphorylation (on
Ser184 or Thr179) by GSK3 occurs. Phosphorylation by glycogen
synthase kinase-3 (GSK3) induces S phase entry and thereby
mitotic clonal expansion (MCE), a requirement for terminal differ-
entiation. BecauseMAPK activity is down-regulated before S phase
is completed, we sought to identify the kinase that maintains
C/EBP in the primed phosphorylated state throughout S phase
and MCE. We show here that cdk2/cyclinA, whose expression is
activated at the onset of S phase, functions in this capacity. Ex vivo
and in vitro experiments show that cdk2/cyclinA catalyzes this
delayed priming phosphorylation. Mass spectrometric analysis
revealed that cdk2/cyclinA phosphorylates C/EBP on Thr188 and is
required for phosphorylation (on Ser184 or Thr179) of C/EBP by
GSK3 and maintenance of DNA binding activity. Suppression of
cdk2 activity by RNA interference or pharmacologic inhibitor dis-
rupts subsequent events in the differentiation program. Thus,
MAPK and cdk2/cyclinA act sequentially to maintain Thr188 of
C/EBP in the primed phosphorylated state during MCE and
thereby progression of terminal differentiation.
3T3-L1 adipocyte  adipose  cell cycle  mitotic clonal expansion  obesity
When induced to differentiate, growth-arrested 3T3-L1preadipocytes in G1 phase synchronously reenter the cell
cycle, undergo two rounds of mitosis [(mitotic clonal expansion
(MCE)], then exit the cell cycle and commence terminal differ-
entiation into adipocytes (1, 2). Fourteen hours after induction,
preadipocytes traverse the G1/S checkpoint as evidenced by the
expression/activation of cdk2 and cyclinA, the turnover of p27/
kip1, hyperphosphorylation of Rb protein, translocation of
glycogen synthase kinase-3 (GSK3) into the nucleus and
cyclinD1 from the nucleus, and incorporation of [3H]thymidine
into DNA (1). Blocking these steps disrupts MCE and progres-
sion of the differentiation program. The synchrony by which
3T3-L1 preadipocytes proceed through MCE has been invalu-
able in delineating the sequence of events that occur early in the
adipocyte differentiation program (2, 3).
Upon induction of differentiation CCAAT/enhancer binding
protein- (C/EBP) is expressed immediately (2 h), triggering
a transcriptional cascade by transcriptionally inducing the ex-
pression of C/EBP and peroxisome proliferator-activated re-
ceptor  (PPAR) (4–7). C/EBP and PPAR are pleiotropic
transcriptional activators of genes that give rise to the adipocyte
phenotype (4, 8–10). Although C/EBP is expressed 2 h after
induction, it lacks DNA-binding and transactivation activity (11).
These activities are acquired only after a long (14 h) lag.
Acquisition of DNA binding activity occurs concomitant with
the entry of S phase at theG1/S checkpoint and the onset ofMCE
(11). This lag appears to be required, because C/EBP is
antimitotic (12–14) and its premature expression would other-
wise prevent MCE, during which chromatin remodeling is
thought to provide access of C/EBP and PPAR to adipocyte
gene promoters. It should be noted that sequestration of C/EBP
with a dominant-negative A-Zip blocks its entry into the nucleus,
preventing MCE and thus terminal differentiation (15). Like-
wise, MCE and terminal differentiation are disrupted in
C/EBP/ mouse embryo fibroblasts (16).
Previous studies have shown that C/EBP is sequentially
phosphorylated during differentiation of 3T3-L1 adipocytes (3),
first by MAPK (on Thr188) in G1 phase and later by GSK3 (on
Ser184 or Thr179) at the onset of S phase concurrent with the
translocation of GSK3 into the nucleus. Phosphorylation of
Thr188 appears to prime C/EBP for subsequent phosphoryla-
tion on Ser184 or Thr179, which lie immediately upstream of the
priming site. Recent studies indicate that this dual phosphory-
lation induces a conformational change in C/EBP that allows
dimerization through its C-terminal leucine zipper domain (17).
Dimerization brings the adjacent apposing basic regions into
position to hold the C/EBP regulatory element of the gene in a
‘‘scissors-like’’ grip as suggested by McKnight and colleagues
(18). Together, these actions are believed to facilitate acquisition
of DNA-binding activity and transcription.
However, because expression of MAPK activity is transient
and abruptly decreases 14–16 h after induction, the following
question must be considered: How is the ‘‘priming’’ phosphor-
ylation at Thr188 maintained during the subsequent period of S
phase and MCE when dual phosphorylation by GSK3 occurs?
This issue is addressed in the present paper. Here we show that
in both cellular and in vitro contexts, C/EBP undergoes phos-
phorylation on Thr188 by cdk2/cyclinA, which primes the target
region for further phosphorylation by GSK3. Together, these
phosphorylations give rise to DNA binding activity. Our results
indicate that MAPK and cdk2/cyclinA act sequentially to main-
tain Thr188 of C/EBP in the primed phosphorylated state for
phosphorylation by GSK3 throughout MCE.
Results
C/EBP Is Phosphorylated on Thr188 by cdk2/cyclinA During Differen-
tiation of 3T3-L1 Preadipocytes. Consistent with findings in ref. 3,
C/EBP is rapidly (4 h) expressed and phosphorylated on
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Thr188 after induction of differentiation (Fig. 1A). This priming
phosphorylation at Thr188 is catalyzed by MAPK and required
for subsequent phosphorylation by GSK3 and the acquisition
of DNA binding activity by C/EBP (3). MAPK/ERK itself is
rapidly (1 h) phosphorylated/activated after induction of dif-
ferentiation (Fig. 1B) (3). Although phosphorylation of C/EBP
on Thr188 persists at a high level for 24 h (Fig. 1A and ref. 3),
the phosphorylation/activity of MAPK [phospho-ERK (P-
ERK)] falls off abruptly after 10–12 h. This finding raises the
question of how this priming phosphorylation, which is required
for subsequent phosphorylation by GSK3 (3), is maintained
throughout S phase and MCE. Several findings suggested cdk2
as the candidate priming kinase for S phase progression. First,
cdk2 is known to phosphorylate rat C/EBP on Thr189 [equiv-
alent to Thr188 in mouse C/EBP (19)]. Furthermore, the
expression of both cdk2 and cyclinA is coordinately activated,
concomitant with the turnover of p27/kip (a cdk2/cyclinA in-
hibitor) during this time window of the differentiation pro-
gram (1).
To determine whether cdk2/cyclinA has the potential to act as
the priming kinase, cdk2/cyclinA was immunoprecipitated from
3T3-L1 cells 20 h after induction and the decline of P-ERK/
MAPK (Fig. 1B). It is evident that, at 20 h, cdk2/cyclinA is active
as indicated by its ability to phosphorylate both histone H1 (Fig.
2A) and purified rC/EBP (Fig. 2B). Furthermore, treatment of
the cells with roscovitine, a potent cdk2/cyclinA inhibitor, rap-
idly reduces the phosphorylation of C/EBP (see below).
In vitro experiments with recombinant C/EBP and
[-32P]ATP verified that cdk2/cyclinA phosphorylates C/EBP
(Fig. 3A) that phosphorylation occurs on Thr188 (Fig. 3B) as it
does with MAPK (3). To ascertain the number of sites phos-
phorylated by cdk2/cyclinA (or MAPK), the reaction products
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Fig. 2. C/EBP is a substrate for cdk2/cyclinA. Two-day postconfluent 3T3-L1
preadipocytes were induced to differentiate, and 20 h later nuclear extracts
were prepared and cdk2/cyclinA was immunoprecipitated and incubated with
purified histone H1 (A) or purified recombinant C/EBP (B) in the presence of
[-32P]ATP. After SDS/PAGE, [32P]histone H1 (AUpper) or [32P]C/EBP (BUpper)
was detected by autoradiography. Total histone H1(A Lower) and C/EBP (B
Lower) were detected by Coomassie blue staining. Pi refers to preimmune
serum.
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Fig. 3. Thr188 of C/EBP is phosphorylated both by MAPK and cdk2/cyclinA.
(A) rC/EBP was incubated without or with MAPK or cdk2/cyclinA and
[-32P]ATP. After SDS/PAGE, [32P]C/EBP was detected by autoradiography
(Upper), and total C/EBP was detected by Coomassie blue staining (Lower);
Similar experiments were performed as above but with cold ATP. (B) Immu-
noblotting was with anti-P-Thr188-C/EBP (Upper) or anti-C/EBP (Lower) an-
tibodies. (C) The C/EBP band was excised from the gel, digested by trypsin,
and analyzed by nanoLC-MS/MS. A singly phosphorylated peptide species
from C/EBP was observed (m/z 1,094.8) with MAPK or cdk2/cyclinA (Middle
and Bottom, respectively). No phosphorylation was observed in the same
peptide (m/z 1,067.5) without kinase treatment (Top).
42026121840srH ,emiT
PBE/C β
rhT-P 881 PBE/C- β
A
KRE
KRE-P
4202612184210srH ,emiTB
srH ,emiT
2kdc
42026121840C
sruoH
D
0
02
04
06
08
001
62422202816141210186420
%
rhT-p 881 PBE/C- β
2kdcKRE-P
Fig. 1. Changes in the levels of C/EBP, ERK, and cdk2 and phosphorylation
states of C/EBP/Thr188 and ERK during differentiation of 3T3-L1 preadipo-
cytes. Two-day postconfluent 3T3-L1 preadipocytes were induced to differ-
entiate, and cell extracts were prepared, subjected to SDS/PAGE, and immu-
noblotted with antibodies to C/EBP, P-Thr188-C/EBP (A), ERK, P-ERK (B), and
cdk2 (C); relative levels are plotted (D).
11598  www.pnas.orgcgidoi10.1073pnas.0703771104 Li et al.
were separated by SDS/PAGE, and the protein band corre-
sponding to C/EBP was excised, digested with trypsin, and
subjected to mass spectrometry. Nanospray MS showed that
phosphorylation of rC/EBP by either cdk2/cyclinA or MAPK
gave rise to a singly phosphorylated triply charged species of the
correct mass (m/z, 1,094.8) (Fig. 3C Middle and Bottom). Iden-
tification of the phosphorylation site was also verified by mass
spectrometry. The site phosphorylated by cdk2/cyclinA [sup-
porting information (SI) Fig. 8] or MAPK (data not shown, see
ref. 3) was identified as Thr188.
Phosphorylation of Thr188 by cdk2/cyclinA Primes C/EBP for Phos-
phorylation by GSK3. Phosphorylation of C/EBP by MAPK at
Thr188 is required for hyperphosphorylation of C/EBP at Thr179
or Ser184 by GSK3 (3). Likewise, phosphorylation at Thr188 by
cdk2/cyclinA primes C/EBP for phosphorylation by GSK3.
Thus, incubation of cdk2/cyclinA (or MAPK), GSK3, and
[-32P]ATP leads to phosphorylation of purified rC/EBP,
whereas in the absence of cdk2/cyclinA, GSK3 alone does not
support phosphorylation (Fig. 4A). Incubation with cdk2/cyclinA
(or MAPK) in combination with GSK3 produced a level of
phosphorylation approximately twice that by cdk2/cyclinA or
MAPK alone (Fig. 4A). This finding indicates that phosphory-
lation by cdk2/cyclinA (or MAPK) primes C/EBP for further
phosphorylation by GSK3. It should also be noted that phos-
phorylation by cdk2/cyclinA (or MAPK) slows the mobility of
C/EBP slightly (Figs. 4A and 5A) and that dual phosphorylation
by cdk2/cyclinA (or MAPK) and GSK3 slows it even more
(Fig. 5A).
The extent of phosphorylation of rC/EBP by the combined
kinases was verified by mass spectrometry. After separation by
SDS/PAGE, the protein band corresponding to C/EBP was
excised, digested with trypsin, and subjected to nano liquid
chromatography (LC)-MS/MS analysis. This analysis identified a
doubly phosphorylated peptide (m/z, 1,121.0) when C/EBP was
incubated with both cdk2/cyclinA and GSK3 or both MAPK
and GSK3 (Fig. 4B). To identify the specific amino acids in
rC/EBP phosphorylated in vitro, experiments similar to those
above were performed. MS/MS analysis of C/EBP incubated
with cdk2/cyclinA and GSK3 revealed two doubly phosphor-
ylated peptide species, one phosphorylated at Thr188 and Ser184
(SI Fig. 9) and another phosphorylated at Thr188 and Ser179 (data
not shown). No phosphorylation product was detected with
GSK3 alone. Together, these findings show that C/EBP can
also be phosphorylated at Thr188 by cdk2/cyclinA and that this
phosphorylation serves as the priming site for phosphorylation
at Ser184/Thr179 by GSK3 in vitro. It should be noted that we
showed in ref. 3 that 20–24 h after induction of differentiation
of 3T3-L1 preadipocytes, the time window in which MAPK
activity is low and cdk2/cyclinA activity is high (Fig. 2 A and B),
both doubly phosphorylated C/EBP peptide species (Thr188 and
Ser184 or Thr179) are present.
Dual Phosphorylation of C/EBP by cdk2/cyclinA and GSK3 Leads to
Acquisition of DNA-Binding Activity. To determine the effect of
phosphorylation of rC/EBP by cdk2/cyclinA with or without
GSK3 onDNA-binding activity, an experiment identical to that
described in Fig. 4 was performed. DNA binding activity was
assessed by EMSA with a labeled oligonucleotide corresponding
to the C/EBP-binding site in the C/EBP gene promoter (7).
DNA-binding activity was acquired only when C/EBP was
phosphorylated by both cdk2/cyclinA and GSK3 (Fig. 5B).
Unphosphorylated C/EBP or C/EBP phosphorylated by cdk2/
cyclinA or MAPK alone had no effect on DNA-binding activity.
Together, these results show that dual phosphorylation of
C/EBP on Thr188 by cdk2/cyclinA and on Ser184 or Thr179 by
GSK3 is required for the acquisition of DNA-binding activity
and that phosphorylation by cdk2/cyclinA alone is insufficient to
increase DNA binding activity.
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Fig. 4. Phosphorylation by either MAPK or cdk2/cyclinA primes C/EBP for
phosphorylation by GSK3. (A) rC/EBPwas incubated without or with MAPK
or cdk2/cyclinA or/and in combination with GSK3 in the presence of
[-32P]ATP. After SDS/PAGE [32P]C/EBP was detected by autoradiography
(Upper), and protein was detected by Coommassie blue staining (Lower).
Similar experiments were performed but with cold ATP. (B) The C/EBP band
was excised from the gel, digested with trypsin, and analyzed by nanoLC-MS/
MS. A doubly phosphorylated peptide species was observed (m/z 1,121.0) with
C/EBP incubated with MAPK plus GSK3 (Middle) or cdk2/cyclinA plus GSK3
(Bottom). No phosphorylation of the peptide (m/z 1,067.5) occurred without
kinase (Top).
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Fig. 5. Phosphorylation of C/EBP by cdk2/cyclinA and GSK3 leads to the
gain of DNA binding activity. In vitro phosphorylation of C/EBP was per-
formed (A) and DNA binding activity was assessed (B).
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Suppression of cdk2 Activity or Expression Decreases Phosphorylation
of C/EBP at Thr188 and Blocks MCE and Differentiation. Brief expo-
sure (4 h) of 3T3-L1 preadipocytes to the potent cdk2 inhibitor,
roscovitine, as the cells enter S phase (1) markedly lowers
phosphorylation of Thr188 in C/EBP (Fig. 6 A and B). Although
the level of C/EBP was also partially lowered by inhibitor
treatment, the level of phosphorylation was more drastically
affected, raising the possibility that the turnover of C/EBPmay
be preceded and accelerated by phosphorylation. It should be
noted that, in previous experiments (1), we showed that treat-
ment with roscovitine in this time window blocked MCE, the
expression of differentiation markers, and acquisition of adipo-
cyte characteristics.
Reducing the expression of cdk2 by RNA interference had
similar effects. Several siRNA oligonucleotides (23 mers), cor-
responding to diverse regions in the cdk2 mRNA sequence, were
tested initially for their ability to silence cdk2 expression. The
most active of these oligonucleotides virtually abolished expres-
sion of cdk2 (Fig. 7A). Proliferating 3T3-L1 preadipocytes were
exposed to this oligonucleotide and later treated with differen-
tiation inducers (at confluence) under conditions similar to
those of the standard differentiation protocol. As shown in Fig.
6 C and D, lowering cdk2 by RNA interference almost com-
pletely blocked the phosphorylation of Thr188 in C/EBP. Con-
sistent with the results with roscovitine (see above), blocking
phosphorylation of Thr188 only partially reduced the level of
C/EBP (Fig. 6A and 7A). Moreover, suppressing expression of
cdk2 or C/EBP by RNA interference blocked MCE (Fig. 7B),
suppressed the expression of differentiation markers (Fig. 7D),
and prevented the accumulation of cytoplasmic triglyceride (Fig.
7C), an indicator of adipogenesis. Taken together, these findings
suggest that cdk2, which catalyzes the priming phosphorylation
of Thr188 in C/EBP (Figs. 3–5), is required for MCE and
differentiation. It should be noted that because cdk2 has other
roles, it is possible that its inactivation also acts at another site
in the cell cycle.
Discussion
During differentiation of 3T3-L1 preadipocytes C/EBP under-
goes a priming phosphorylation on Thr188 followed by an addi-
tional phosphorylation on Ser184 or Thr179 by GSK3 to produce
dually phosphorylated species that bind to and transactivate
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Fig. 6. Suppression of cdk2 activity with roscovitine or by RNA interference
decreases phosphorylation of C/EBP on Thr188. (A and B) Day-0 3T3-L1 prea-
dipocytes were treated with or without a cdk2 inhibitor (roscovitine, 25 M)
1 h before induction of differentiation. (A) Cell extracts, prepared 20 h after
induction, were subjected to SDS/PAGE and immunoblotted with anti-C/EBP
(Top) or anti-P-Thr188-C/EBP (Middle) antibodies. (B) Relative levels were
quantified. (C and D) 3T3-L1 preadipocytes were treated with 40 nM of cdk2
RNAi or an irrelevant RNAi control, and the effects on C/EBP expression (C
Top) or phosphorylation of Thr188 (C Middle) were quantified (D). (A Bottom
and C Bottom) Shown is a nonspecific loading control (NSB).
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Fig. 7. RNA interference with cdk2 or C/EBP siRNA prevents MCE and
differentiation. 3T3-L1 preadipocytes were treated with cdk2 or C/EBP siRNA
(40 nM) at 30–50% confluency by using Lipofectamine RNAi Max, and 24 h
later cells were trypsinized and replated at confluent cell density. After 24 h,
cells were induced to differentiate. (A) Twenty hours after induction, cell
extracts were prepared, and the effects on the expression of cdk2 (Middle) and
C/EBP (Top) were analyzed. (Bottom) Shown is a nonspecific loading control
(NSB). (B) Cell number on day 4. (C) Oil red O staining on day 8. (D) Expression
of PPAR and 422/aP2 on day 6.
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genes that produce the adipocyte phenotype (4, 8–10). In this
paper, we show that the priming phosphorylation occurs at two
points in the differentiation program: an initial phosphorylation
by MAPK followed much later by phosphorylation by cdk2/
cyclinA when MAPK activity has disappeared. Both priming
phosphorylations occur independently on Thr188 as demon-
strated in in vitro experiments with rC/EBP and the purified
kinases (Figs. 2–4). Phosphorylation at this site is required but
is insufficient for the acquisition of DNA binding function; DNA
binding requires a further phosphorylation by GSK3 (Fig. 5),
as discussed above. We have shown that dual phosphorylation of
Thr188 and of Ser184 induces a conformational change that
facilitates dimerization of C/EBP monomers, creating a DNA
binding pocket that can bind the C/EBP regulatory element in
DNA and support transactivation (17).
The phosphoryl group (phospho-Thr188) on C/EBP, intro-
duced by MAPK, turns over rapidly during the period (2–12 h
after induction of differentiation) in which MAPK/P-ERK ac-
tivity decreases. Rapid turnover of phospho-Thr188 is indicated
by its rapid rate of decline when cdk2 is down-regulated by RNA
interference (Fig. 7 A and B). Because the level of P-Thr188-C/
EBP remains relatively constant during this time window (Fig.
1D), it is evident that normally cdk2 takes over this function
(phosphorylation of C/EBP on Thr188), thereby compensating
for the loss of MAPK activity. The effectiveness of the RNAi
knockdown of cdk2 is indicated by the fact that the terminal steps
in the differentiation program including MCE (Fig. 7B), i.e., the
expression of key adipocyte differentiation markers (Fig. 7D)
and acquisition of the adipose phenotype, are blocked (Fig. 7C)
when cdk2 expression is suppressed (Fig. 7A). This finding also
shows that priming by MAPK cannot replace priming by cdk2/
cyclinA. The requirement of MAPK for the successful initiation
of terminal differentiation has also been demonstrated in earlier
studies by the use of potent MAPK inhibitors (1). Together,
these findings illustrate the importance of both priming phos-
phorylations of C/EBP in orchestrating the differentiation
program. It is now clear that maintaining Thr188 in the primed/
phosphorylated state throughout MCE, is necessary to ensure
phosphorylation by GSK3. Because cdk2 has other roles, it is
possible that its inactivation could act at another point in the cell
cycle and thereby affect differentiation. It is worthy of note that
C/EBP can also be phosphorylated by cdk2 at other sites, i.e.,
S64 and T189, in another context, i.e., in Ras-transformed NIH
cells (19).
It should be noted that this is unlike the situation in mouse
liver where phosphorylation at a different site (S239) in C/EBP
causes exit from the nucleus to the cytoplasm (20). This change
of intracellular localization was attributed to phosphorylation at
a site adjacent to/within the nuclear localization sequence (nls).
Hence, exit from the nucleus correlated with phosphorylation.
Because cdk2 phosphorylates C/EBP on T188, which is imme-
diately succeeded by further phosphorylation (as above) on
Ser184 or Thr179 sites not located at the nls, a change in
localization would not be expected. We have shown that dimer-
ization of C/EBP with A-C/EBP, which obscures the nls,
prevents nuclear entry C/EBP and thereby a blockade of
subsequent events in the differentiation program that involve
C/EBP, e.g., mitotic clonal expansion, expression of adipocyte
genes, and the accumulation of cytoplasmic fat (15).
It is formally possible that one of these kinases targets an
additional, as-yet unidentified phosphorylation site in C/EBP.
Although only a single tryptic peptide product, phosphorylated
(on Thr188) of MAPK or cdk2/cyclinA, was detected in our
analysis (Fig. 4), it is possible that another phosphopeptide
species has eluded detection by mass spectrometry. Although we
have searched for other phosphorylated tryptic peptide species
by mass spectrometry, to date only one phosphopeptide, derived
from kinase-treated rC/EBP, has been identified, i.e., that
phosphorylated on Thr188.
It should also be noted that C/EBP has two known functions
in the adipocyte differentiation program, i.e., the induction of
MCE (15, 16) and transactivation of C/EBP and PPAR (4–7).
Thus, it is conceivable that these distinct functions require
phosphorylation at two different sites. Were this the case,
different phosphorylated species C/EBP might function at
these points in the differentiation program. Whether this occurs
must await further investigation.
Materials and Methods
Cell Culture and Induction of Differentiation. 3T3-L1 preadipocytes
were propagated and maintained in DMEM containing 10%
(vol/vol) calf serum as described in ref. 21. To induce differen-
tiation, 2-day postconfluent/G1 phase preadipocytes (designated
day 0) were fed DMEM containing 10% (vol/vol) FBS (FBS), 1
g/ml insulin, 1 M dexamethasone, and 0.5 mM 3-isobutyl-1-
methylxanthine (MDI) until day 2. Cells were then fed DMEM
supplemented with 10% FBS and 1 g/ml insulin for 2 days, after
which they were fed every other day with DMEM containing
10% FBS. Adipocyte gene expression and acquisition of the
adipocyte phenotype begins on day 3 and is maximal by day 8.
Western Blotting. To follow changes in the level of C/EBP,
P-Thr188-C/EBP, MAPK(ERK), P-ERK and cdk2 proteins
after induction of differentiation, 2-day postconfluent (day 0)
3T3-L1 preadipocytes were treated with MDI in 10% FBS as
above. At various times thereafter, cell monolayers (6-cm dishes)
were washed once with cold PBS (pH 7.4) and then scraped into
lysis buffer containing 1% SDS and 60 mM TrisHCl (pH 6.8).
Lysates were heated at 100°C for 10 min, were clarified by
centrifugation, and equal amounts of protein were subjected to
SDS/PAGE and immunoblotting with antibodies against
C/EBP, P-Thr188-C/EBP, ERK, P-ERK, and cdk2. Antibody
against C/EBP was prepared in this laboratory; antibody
against P-Thr188-C/EBP was from Cell Signaling Technology
(Beverly, MA). Antibodies against MAPK and P-MAPK
(Thr202/Tyr204) were from Upstate Biotechnology (Lake Placid,
NY). Antibody against cdk2 was from Santa Cruz Biotechnology
(Santa Cruz, CA).
Preparation of Recombinant C/EBP(LAP) Protein. The cDNA en-
coding full-length C/EBP(LAP) protein was cloned down-
stream of the GST gene in pGEX-6P (Amersham Pharmacia
Biotech, Piscataway, NJ) and transformed into Escherichia coli
strain BL21(DE3)pLysS (Novagen, San Diego, CA). A single
colony was propagated overnight in 3 ml of LB media containing
ampicillin and chloramphenicol and was then diluted (1:100)
into 500 ml of fresh LB media the next day and cultured until an
A600 of 0.6–0.7 was reached. Expression of the fusion proteins
was induced by addition of 0.5 mM isopropyl -D-thiogalactoside
(IPTG) for 3 h, and the cells were harvested and resuspended in
25 ml of PBS containing 1% Triton X-100. After lysis by one
cycle of freeze–thawing, the cell suspension was treated with
DNase I and RNase A/T1 and then incubated on ice for 10 min
in the presence of 0.5 M NaCl and 5 mM DTT to dissociate the
DNA–protein complex. After centrifugation at 12,000 g for 10
min, 250- to 500-l bead volume of GSH-Sepharose (GE
Healthcare, Piscataway, NJ) was added to the supernatate and
mixed overnight at 4°C. Beads were washed three times with
PBS, once with PreScission cleavage buffer (50 mM Tris-Cl, pH
7.5/150 mM NaCl/1 mM EDTA/1 mM DTT), and then treated
with 80 units of PreScission Protease (GE Healthcare) in 960 l
of buffer. The rC/EBP cleavage product was further purified by
CM-Sepharose chromatography (GE Healthcare), and after
extensive washing with a low salt buffer, the highly purified
recombinant protein eluted 250–300 mM of NaCl. Protein was
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determined by Bradford assay, and purity of the fusion protein
was verified by SDS/PAGE.
Immunoprecipitation and in Vitro Kinase Reaction. Preadipocytes
were induced to differentiate. Nuclear extracts (1) were pre-
pared at 20 h after induction, cdk2/cyclinA was immunoprecipi-
tated from nuclear extracts (50 g of protein) with mouse
monoclonal anti-cdk2 antibody, and the immune complex was
subjected to the in vitro kinase assay with Histone H1 or
rC/EBP as substrates as described in ref. 22.
In Vitro Phosphorylation and Mass Spectrometric Analysis of Full-
Length C/EBP(LAP). Two micrograms of rC/EBP(LAP) was
incubated with (i) activated MAPK (Calbiochem, San Diego,
CA); (ii) cdk2-Cyclin A (Upstate); (iii) GSK3 (Upstate); or
(iv) the combination of MAPK (or cdk2/cyclinA) with GSK3
in buffer containing 50 mM Hepes (pH 7.0), 10 mM MgCl2, 1
mM DTT, and 20 Ci [-32P]ATP (1Ci  37 GBq) at 30°C for
30min. Phosphorylation was detected by autoradiography after
SDS/PAGE. For identification of phosphorylation sites on
C/EBP, similar experiments were performed with 0.5 mM
ATP. The protein band containing C/EBP (38 kDa) was
excised from the gel, digested with trypsin, and analyzed by
nanoLC-MS/MS as described in ref. 23.
EMSA. EMSA was performed essentially as described in ref. 2
with minor modification. Reaction mixtures containing 50,000
cpm of 32P-labeled C/EBP site probe, 0.1 g of poly[d(I-C)], 4 g
of BSA, and 1–10 ng of rC/EBP protein in 30 l of buffer (10
mM Hepes/1 mM EDTA/7% glycerol/1 mM MgCl2/100 mM
NaCl) were incubated on ice for 20min, and proteins were
separated electrophoretically on 4% polyacrylamide gels with
0.25 TBE buffer. The labeled probe included a double-
stranded oligonucleotide corresponding to the sequence of the
C/EBP regulatory element in the C/EBP gene promoter (2),
5-G191CGTTGCGCCACGATCTCTC172-3.
RNAi of cdk2 and C/EBP with siRNA. Synthetic siRNA oligonucle-
otides specific for regions in the cdk2 and C/EBPmRNAs were
designed and synthesized by Invitrogen (Carlsbad, CA) Stealth
RNAi. The silencing effects of several siRNA oligonucleotides
were screened and tested initially for their ability to silence cdk2
or C/EBP expression. The most active of these oligonucleotides
for cdk2 (5 to 3: GCUCGACACUGAGACUGAAGGU-
GUA) and for C/EBP (5 to 3: CCCUGCGGAACUUGUU-
CAAGCAGCU) almost completely blocked the expression of
cdk2 or C/EBP. 3T3-L1 preadipocytes in 60-mm dishes at
30–50% confluency were transfected with siRNA oligonucleo-
tides by using Lipofectamine RNAiMAX (Invitrogen), Twenty-
four hours later, the cells were trypsinized and plated into 35-mm
dishes at cell density of 5  105 cells per dish to generate
confluent monolayers (23). Twenty-four hours later, the cells
were subjected to the standard differentiation protocol, and at
various times thereafter, cell extracts were prepared for analysis.
Two control transfections were performed, one with Lipo-
fectamine RNAiMAX and the other was with Stealth RNAi
Negative Control Duplexes (Invitrogen).
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